Scribe: engineering CRISPR’s next generation

Scribe is carving out a new space in the gene editing landscape with a next-generation version of the technology from Jennifer Doudna’s lab that substitutes engineered CRISPR enzymes for their natural counterparts.

Scribe Therapeutics Inc. emerged from stealth on Tuesday with a $20 million series A round led by Andreessen Horowitz and a deal with Biogen Inc. (NASDAQ:BIIB) that brings the company $15 million up front and potentially more than $400 million in development and commercial milestones, plus tiered, high single-digit to sub-teen royalties...